Beijing Strong Biotechnologies, Inc. (300406.SZ)
CNY 14.73
(-1.73%)
CNY 14.73
(-1.73%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 1.74 Billion CNY | 15.27% |
| 2022 | 1.51 Billion CNY | -5.53% |
| 2021 | 1.59 Billion CNY | 88.58% |
| 2020 | 848.11 Million CNY | 0.86% |
| 2019 | 840.86 Million CNY | 8.61% |
| 2018 | 774.17 Million CNY | 11.51% |
| 2017 | 694.27 Million CNY | 4.03% |
| 2016 | 667.4 Million CNY | 17.87% |
| 2015 | 566.2 Million CNY | 11.4% |
| 2014 | 508.27 Million CNY | 14.32% |
| 2013 | 444.62 Million CNY | 16.96% |
| 2012 | 380.14 Million CNY | 37.75% |
| 2011 | 275.96 Million CNY | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 393.89 Million CNY | -22.45% |
| 2024 Q3 | 415.67 Million CNY | -2.01% |
| 2024 Q2 | 424.21 Million CNY | 7.7% |
| 2023 Q3 | 417.35 Million CNY | -5.77% |
| 2023 Q4 | 507.94 Million CNY | 21.7% |
| 2023 FY | 1.74 Billion CNY | 15.27% |
| 2023 Q1 | 373.39 Million CNY | -3.93% |
| 2023 Q2 | 442.93 Million CNY | 18.62% |
| 2022 FY | 1.51 Billion CNY | -5.53% |
| 2022 Q4 | 388.65 Million CNY | -5.26% |
| 2022 Q3 | 410.21 Million CNY | 20.86% |
| 2022 Q2 | 339.42 Million CNY | -8.9% |
| 2022 Q1 | 372.58 Million CNY | -2.31% |
| 2021 Q1 | 373.68 Million CNY | 16.36% |
| 2021 Q2 | 434.13 Million CNY | 16.18% |
| 2021 FY | 1.59 Billion CNY | 88.58% |
| 2021 Q3 | 410.17 Million CNY | -5.52% |
| 2021 Q4 | 381.39 Million CNY | -7.02% |
| 2020 Q4 | 321.13 Million CNY | 22.72% |
| 2020 Q3 | 261.67 Million CNY | 71.47% |
| 2020 Q2 | 152.6 Million CNY | 35.42% |
| 2020 FY | 848.11 Million CNY | 0.86% |
| 2020 Q1 | 112.69 Million CNY | -58.2% |
| 2019 Q2 | 182.05 Million CNY | 5.7% |
| 2019 FY | 840.86 Million CNY | 8.61% |
| 2019 Q4 | 269.58 Million CNY | 24.25% |
| 2019 Q3 | 216.97 Million CNY | 19.18% |
| 2019 Q1 | 172.24 Million CNY | -28.77% |
| 2018 Q2 | 177.87 Million CNY | 8.98% |
| 2018 Q3 | 191.27 Million CNY | 7.53% |
| 2018 FY | 774.17 Million CNY | 11.51% |
| 2018 Q1 | 163.22 Million CNY | -26.52% |
| 2018 Q4 | 241.79 Million CNY | 26.41% |
| 2017 Q3 | 185.02 Million CNY | 25.59% |
| 2017 Q4 | 222.13 Million CNY | 20.06% |
| 2017 FY | 694.27 Million CNY | 4.03% |
| 2017 Q1 | 139.78 Million CNY | -24.2% |
| 2017 Q2 | 147.32 Million CNY | 5.39% |
| 2016 Q1 | 149.45 Million CNY | -8.23% |
| 2016 Q2 | 145.44 Million CNY | -2.68% |
| 2016 FY | 667.4 Million CNY | 17.87% |
| 2016 Q4 | 184.42 Million CNY | -1.94% |
| 2016 Q3 | 188.07 Million CNY | 29.31% |
| 2015 Q2 | 140.91 Million CNY | 12.43% |
| 2015 Q1 | 125.33 Million CNY | -13.61% |
| 2015 Q4 | 162.85 Million CNY | 18.78% |
| 2015 FY | 566.2 Million CNY | 11.4% |
| 2015 Q3 | 137.09 Million CNY | -2.71% |
| 2014 Q4 | 145.08 Million CNY | 10.16% |
| 2014 Q2 | 121.53 Million CNY | 10.53% |
| 2014 Q1 | 109.95 Million CNY | -6.0% |
| 2014 FY | 508.27 Million CNY | 14.32% |
| 2014 Q3 | 131.7 Million CNY | 8.37% |
| 2013 FY | 444.62 Million CNY | 16.96% |
| 2013 Q4 | 116.97 Million CNY | 4.93% |
| 2013 Q3 | 111.47 Million CNY | 0.0% |
| 2012 FY | 380.14 Million CNY | 37.75% |
| 2011 FY | 275.96 Million CNY | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Dian Diagnostics Group Co.,Ltd. | 13.4 Billion CNY | 87.011% |
| Hangzhou Tigermed Consulting Co., Ltd. | 7.38 Billion CNY | 76.414% |
| Dirui Industrial Co.,Ltd. | 1.36 Billion CNY | -27.749% |
| Medicalsystem Biotechnology Co., Ltd. | 1.88 Billion CNY | 7.649% |
| Maccura Biotechnology Co.Ltd | 2.89 Billion CNY | 39.856% |
| Guangzhou Wondfo Biotech Co.,Ltd | 2.76 Billion CNY | 37.01% |
| Guangdong Hybribio Biotech Co.,Ltd. | 1.1 Billion CNY | -57.691% |
| BGI Genomics Co., Ltd. | 4.34 Billion CNY | 59.959% |
| Amoy Diagnostics Co., Ltd. | 1.03 Billion CNY | -67.652% |
| Shanghai Labway Clinical Laboratory Co., Ltd. | 1.67 Billion CNY | -4.017% |